Bristol-Myers Squibb Company (BMY)

UPDATE 3-US FDA approves expanded use of Bristol Myers' cancer cell therapy

The U.S. health regulator on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi for the treatment of adults with a type of blood cancer called follicular lymphoma, that has returned or has not responded to prior treatments. The Food and Drug Administration's decision marks the fourth approval for Breyanzi, which can now be used to treat patients who have received two or more prior lines of therapy. The approval provides an option with potential for lasting remission in a one-time infusion and a safety profile that allows for administration and monitoring in an increasing number of certified treatment centers in the U.S., said Bryan Campbell, Bristol Myers' head of commercial cell therapy in a statement.